BioCentury
ARTICLE | Company News

Aposense, Teva deal

June 21, 2010 7:00 AM UTC

Teva plans to invest up to an additional $9 million in its September 2005 deal with Aposense to co-develop therapeutics comprised of an Aposense probe conjugated to generic cytotoxic agents to treat c...